The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 15, 2005
Filed:
Dec. 17, 1999
(hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
Darin A. Allen, Moutain View, CA (US);
Jason M. Hataye, San Francisco, CA (US);
Witold N. Hruzewicz, San Francisco, CA (US);
Aleksandr Kolesnikov, San Francisco, CA (US);
Richard L. Mackman, San Francisco, CA (US);
Roopa Rai, San Carlos, CA (US);
Spencer R. Jeffrey, So. San Francisco, CA (US);
Erik J. Verner, Foster City, CA (US);
Wendy B. Young, San Mateo, CA (US);
William Dvorak Shrader, Belmont, CA (US);
Darin A. Allen, Moutain View, CA (US);
Jason M. Hataye, San Francisco, CA (US);
Witold N. Hruzewicz, San Francisco, CA (US);
Aleksandr Kolesnikov, San Francisco, CA (US);
Richard L. Mackman, San Francisco, CA (US);
Roopa Rai, San Carlos, CA (US);
Spencer R. Jeffrey, So. San Francisco, CA (US);
Erik J. Verner, Foster City, CA (US);
Wendy B. Young, San Mateo, CA (US);
William Dvorak Shrader, Belmont, CA (US);
Axys Pharmaceuticals, Inc., So. San Francisco, CA (US);
Abstract
The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.